---
figid: PMC8264452__fimmu-12-692219-g001
figtitle: Use of Biologic Modifiers as a Bridge to Hematopoietic Cell Transplantation
  in Primary Immune Regulatory Disorders
organisms:
- Homo sapiens
- Mus musculus
- Human gammaherpesvirus 4
- unidentified
- NA
organisms_ner:
- Mus musculus
- Homo sapiens
- Danio rerio
pmcid: PMC8264452
filename: fimmu-12-692219-g001.jpg
figlink: /pmc/articles/PMC8264452/figure/f1/
number: F1
caption: Biology of Precision Based Therapies. (A) CTLA4-Ig binds to CD80/86 effectively
  replacing the non-functional CTLA-4 protein. (B) Gain of Function mutations in PIK3CD
  or PIK3RI result in Activated PI3K d Syndrome. Leniolisib inhibits PI3K activation
  directly and sirolimus inhibits downstream enhanced mTORC1 activity. (C) Gain of
  function mutations in STAT1 and STAT3 cause hyperactivation STAT1 and STAT3 respectively.
  Jakinibs are direct inhibitors of the JAK/STAT pathway.
papertitle: The Use of Biologic Modifiers as a Bridge to Hematopoietic Cell Transplantation
  in Primary Immune Regulatory Disorders.
reftext: Danielle E. Arnold, et al. Front Immunol. 2021;12:692219.
year: '2021'
doi: 10.3389/fimmu.2021.692219
journal_title: Frontiers in Immunology
journal_nlm_ta: Front Immunol
publisher_name: Frontiers Media S.A.
keywords: PIRD | CTLA4 | Pi3Kinase | STAT1 | STAT3 | Jakinib | Abatacept | Emapalumab
automl_pathway: 0.9638349
figid_alias: PMC8264452__F1
figtype: Figure
redirect_from: /figures/PMC8264452__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8264452__fimmu-12-692219-g001.html
  '@type': Dataset
  description: Biology of Precision Based Therapies. (A) CTLA4-Ig binds to CD80/86
    effectively replacing the non-functional CTLA-4 protein. (B) Gain of Function
    mutations in PIK3CD or PIK3RI result in Activated PI3K d Syndrome. Leniolisib
    inhibits PI3K activation directly and sirolimus inhibits downstream enhanced mTORC1
    activity. (C) Gain of function mutations in STAT1 and STAT3 cause hyperactivation
    STAT1 and STAT3 respectively. Jakinibs are direct inhibitors of the JAK/STAT pathway.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Apc
  - Cd86
  - Ctla4
  - Lrba
  - Pik3r1
  - Akt1
  - Pdk1
  - Pdpk1
  - Stat3
  - APC
  - PROC
  - CD86
  - CTLA4
  - LRBA
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - MAPKAP1
  - MTOR
  - RICTOR
  - MLST8
  - AKT1
  - AKT2
  - AKT3
  - PDK1
  - PDPK1
  - RPTOR
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - SOAT1
  - STAT1
  - STAT2
  - STAT3
  - STAT4
  - STAT6
  - STAT5A
  - STAT5B
  - apc
  - lrba
  - pdk1
  - stat1b
  - stat4
  - stat3
---
